Top

Published in:

01-06-2015 | Lymphoma (JW Sweetenham, Section Editor)

The Role of Infectious Agents, Antibiotics, and Antiviral Therapy in the Treatment of Extranodal Marginal Zone Lymphoma and Other Low-Grade Lymphomas

Authors: Laahn H. Foster, MD, Craig A. Portell, MD

Published in: Current Treatment Options in Oncology | Issue 6/2015

Opinion statement

There is strong evidence to corroborate the association with Helicobacter pylori (Hp) to gastric extranodal marginal zone lymphoma (ENMZL) and hepatitis C virus (HCV) to splenic/nodal marginal zone lymphoma. Koch’s postulates generally hold for these two associations and eradication of the infectious agent is well supported. Hp eradication (HPE) is recommended as front-line therapy for early stage gastric ENMZL regardless of Hp status. Complete response (CR) rate for Hp-negative patients is not as high as for Hp-positive patients; however, the benign nature of HPE and high rates of salvage allow this strategy to be safe while sparing some Hp-negative patients from systemic therapy or radiation. Similarly for HCV-seropositive patients, treatment with antivirals should be strongly considered as first-line for those who do not require immediate cytoreductive therapy or at some point even after completing chemoimmunotherapy. The controversy regarding the role for antibiotics is greatest for primary ocular adnexal lymphoma (POAL). Considering the low incidence of Chlamydia psittaci (Cp) infection with OAL and the challenges to reliably identifying Cp, we typically do not consider doxycycline in POAL treatment. Involved-field radiotherapy (IFRT) remains the treatment of choice for most with unilateral POAL. However, if reliable detection of Cp is available and Cp is identified, patients with unilateral low tumor stage POAL who do not require immediate radiotherapy could be considered for doxycycline as front-line treatment. Other infectious associations to indolent lymphomas have been made, including Borrelia borgdorferi (Bb) in cutaneous lymphoma and Campylobacter in immunoproliferative small intestinal disease (IPSID), but these associations are not as strong and primary treatment targeting the infectious agents is not recommended.

1.••

Bracci PM, Benavente Y, Turner JJ, et al. Medical history, lifestyle, family history, and occupational risk factors for marginal zone lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;48:52–65. This study pooled data from 1052 MZL cases and 13766 controls to identify risk factors associated with the development of MZL.

Suarez F, Lortholary O, Hermine O, Lecuit M. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood. 2006;107(8):3034–44.PubMedCrossRef

Gradmann C. A spirit of scientific rigour: Koch’s postulates in twentieth-century medicine. Microbes Infect. 2014;16(11):885–92.PubMedCrossRef

Nakamura S, Matsumoto T, Ye H, et al. Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: a clinicopathologic and molecular study with reference to antibiotic treatment. Cancer. 2006;107(12):2770–8.PubMedCrossRef

5.•

Zucca E, Copie-Bergman C, Ricardi U, Thieblemont C, Raderer M, Ladetto M. Gastric marginal zone lymphoma of MALT type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Supplement 6):vi144–8. This study outlines current practice guidelines for gastric ENMZL.

Zullo A, Hassan C, Cristofari F, et al. Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol. 2010;8(2):105–10.PubMedCrossRef

7.•

Nakamura S, Sugiyama T, Matsumoto T, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut. 2012;61(4):507–13. This is a large study that confirmed the long-term efficacy associated with first-line HPE for gastic MALT lymphoma, similar to the results shown by an early meta-analysis [5].

Wündisch T, Dieckhoff P, Greene B, et al. Second cancers and residual disease in patients treated for gastric mucosa-associated lymphoid tissue lymphoma by Helicobacter pylori eradication and followed for 10 years. Gastroenterology. 2012;143(4):936–42.

Choi YJ, Kim N, Paik JH, et al. Characteristics of Helicobacter pylori-positive and Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma and their influence on clinical outcome. Helicobacter. 2013;18:197–205.PubMedCrossRef

10.•

Zullo A, Hassan C, Ridola L, et al. Eradication therapy in Helicobacter pylori-negative gastric low-grade MALT lymphoma patients: a systemic review. J Cinical Gastroenterol. 2013;47(10):824–7. This is the largest systemic review that demonstrates the impact of HPE in Hp-negative gastric ENMZL and suggests a select group of these patients can be successfully treated with antibiotics alone.

11.

Al-Taie O, Al-Taie E, Fischbach W. Patients with Helicobacter pylori negative gastric marginal zone b-cell lymphoma (MZBCL) of MALT have a good prognosis. Z Gastroenterol. 2014;52(12):1389–93.PubMedCrossRef

12.

Raderer M, Wöhrer S, Kiesewetter B, et al. Antibiotic treatment as sole management of Helicobacter pylori-negative gastric MALT lymphoma: a single center experience with prolonged follow-up. Ann Hematol. 2015

13.

Engels EA, Chatterjee N, Cerhan JR, et al. Hepatitis C virus infection and non-Hodgkin lymphoma: results of the NCI-SEER multi-center case-control study. Int J Cancer. 2004;111(1):76–80.PubMedCrossRef

14.

Nieters A, Kallinowski B, Brennan P, et al. Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH. Gastroenterology. 2006;131(6):1879–86.PubMedCrossRef

15.

De Sanjose S, Benavente Y, Vajdic CM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol. 2008;6(4):451–8.PubMedCentralPubMedCrossRef

16.••

Morton LM, Slager SL, Cerhan JR, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;48:130–44. This is a very large study that pooled data from 17,471 NHL cases and 23,096 controls to identify risk factors associated with different NHL subtypes. This study overcomes the limitations associated with smaller studies and showed the increased risk of HCV with certain NHL subtypes.

17.

Kawamura Y, Ikeda K, Arase Y, et al. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med. 2007;120(12):1034–41.PubMedCrossRef

18.

Mazzaro C, De Re V, Spina M, et al. Pegylated-interferon plus ribavirin for HCV-positive indolent non-Hodgkin lymphomas. Br J Haematol. 2009;145(2):255–7.PubMedCrossRef

19.

Vallisa D, Bernuzzi P, Arcaini L, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin’s lymphoma: a multicenter Italian experience. J Clin Oncol. 2005;23(3):468–73.PubMedCrossRef

20.

Kelaidi C, Rollot F, Park S, et al. Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas. Leukemia. 2004;18(10):1711–6.PubMedCrossRef

21.

Tursi A, Brandimarte G, Torello M. Disappearance of gastric mucosa-associated lymphoid tissue in hepatitis C virus-positive patients after anti-hepatitis C virus therapy. J Gastroenterol. 2004;38(4):360–3.

22.

Arcaini L, Merli M, Volpetti S, Rattotti S, Gotti M, Zaja F. Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy. Clin Dev Immunol. 2012;2012:638185.PubMedCentralPubMedCrossRef

23.

Saadoun D, Suarez F, Mariette X, et al. Brief report splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity? Blood. 2005;105(1):74–6.PubMedCrossRef

24.

Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;384(9941):403–13.PubMedCrossRef

25.

Flamm SL, Lawitz E, Jacobson I, et al. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol. 2013;11(1):81–7.PubMedCrossRef

26.•

Arcaini L, Vallisa D, Rattotti S, et al. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Ann Oncol. 2014;25(7):1404–10. This is currently the largest study demonstrating the efficacy of first- or second-line AT in HCV-related indolent NHL that correlated to HCV-RNA clearance.

27.•

Michot J-M, Canioni D, Driss H, et al. Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study. Am J Hematol. 2015;90(3):197-203. This study reinforces the results of [26] and also demonstrated favorable OS benefits associated with AT therapy.

28.

Ferry JA, Fung CY, Zukerberg L, et al. Lymphoma of the ocular adnexa: a study of 353 cases. Am J Surg Pathol. 2007;31(2):170–84.PubMedCrossRef

29.

Portell CA, Aronow ME, Rybicki LA, Macklis R, Singh AD, Sweetenham JW. Clinical characteristics of 95 patients with ocular adnexal and uveal lymphoma: treatment outcomes in extranodal marginal zone subtype. Clin Lymphoma Myeloma Leuk. 2014;14(3):203–10.PubMedCrossRef

30.

Aronow ME, Portell CA, Rybicki LA, Sweetenham JW, Singh AD. Ocular adnexal lymphoma: assessment of a tumor-node-metastasis staging system. Ophthalmology. 2013;120(9):1915–9.PubMedCrossRef

31.

Harada K, Murakami N, Kitaguchi M, et al. Localized ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiation therapy: a long-term outcome in 86 patients with 104 treated eyes. Int J Radiat Oncol Biol Phys. 2014;88(3):650–4.PubMedCrossRef

32.

Ohga S, Nakamura K, Shioyama Y, et al. Radiotherapy for early-stage primary ocular adnexal mucosa-associated lymphoid tissue lymphoma. Anticancer Res. 2013;33(12):5575–8.PubMed

33.

Fung CY, Tarbell NJ, Lucarelli MJ, et al. Ocular adnexal lymphoma: clinical behavior of distinct World Health Organization classification subtypes. Int J Radiat Oncol. 2003;57(5):1382–91.CrossRef

34.

Lim S-H, Kang M, Son J. Extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue type of the ocular adnexa: retrospective single institution review of 95 patients. Indian J Ophthalmol. 2011;59(4):273–7.PubMedCentralPubMedCrossRef

35.•

Olszewski AJ, Desai A. Radiation therapy administration and survival in stage I/II extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Int J Radiat Oncol Biol Phys. 2014;88(3):642–9. This is a large population-based analysis extracting data on 7774 patients with stage I/II MALT lymphoma from the SEER database and showed excellent survival in most sites of origin and negligible lymphoma-related death for ocular lymphoma.

36.

Ferreri AJM, Guidoboni M, Ponzoni M, et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst. 2004;96(8):586–94.PubMedCrossRef

37.

Ruiz A, Reischl U, Swerdlow SH, et al. Extranodal marginal zone B-cell lymphomas of the ocular adnexa: multiparameter analysis of 34 cases including interphase molecular cytogenetics and PCR for Chlamydia psittaci. Am J Surg Pathol. 2007;31(5):792–802.PubMedCrossRef

38.

Carugi A, Onnis A, Antonicelli G, et al. Geographic variation and environmental conditions as cofactors in Chlamydia psittaci association with ocular adnexal lymphomas: a comparison between Italian and African samples. Hematol Oncol. 2010;28(1):20–6.PubMed

39.

Chanudet E, Zhou Y, Bacon CM, et al. Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions. J Pathol. 2006;209(3):344–51.PubMedCrossRef

40.

Zhang D, Dong L, Li H, et al. Ocular adnexal mucosa-associated lymphoid tissue lymphoma in Northern China: high frequency of numerical chromosomal changes and no evidence of an association with Chlamydia psittaci. Leuk Lymphoma. 2010;51(11):2031–8.PubMedCrossRef

41.

Rosado MF, Byrne GE, Ding F, et al. Ocular adnexal lymphoma: a clinicopathologic study of a large cohort of patients with no evidence for an association with Chlamydia psittaci. Blood. 2006;107(2):467–72.PubMedCentralPubMedCrossRef

42.

Husain A, Roberts D, Pro B, McLaughlin P, Esmaeli B. Meta-analyses of the association between Chlamydia psittaci and ocular adnexal lymphoma and the response of ocular adnexal lymphoma to antibiotics. Cancer. 2007;110(4):809–15.PubMedCrossRef

43.

Ferreri AJM, Dolcetti R, Dognini GP, et al. Chlamydophila psittaci is viable and infectious in the conjunctiva and peripheral blood of patients with ocular adnexal lymphoma: results of a single-center prospective case-control study. Int J Cancer. 2008;123(5):1089–93.PubMedCrossRef

44.•

Ferreri AJM, Govi S, Pasini E, et al. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol. 2012;30(24):2988–94. This is prospective multi-center trial that showed OAL regression with first-line doxycycline in Cp-positive patients and has introduced the possibility of treating a very select group of these patients with antibiotics.

45.

Han JJ, Kim TM, Jeon YK, et al. Long-term outcomes of first-line treatment with doxycycline in patients with previously untreated ocular adnexal marginal zone B cell lymphoma. Ann Hematol. 2015;94(4):575–81.

46.

Lee MJ, Min B-J, Choung H-K, Kim N, Kim YA, Khwarg SI. Genome-wide DNA methylation profiles according to Chlamydophila psittaci infection and the response to doxycycline treatment in ocular adnexal lymphoma. Mol Vis. 2014;20:1037–47.PubMedCentralPubMed

47.

Ferreri AJM, Ponzoni M, Guidoboni M, et al. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J Natl Cancer Inst. 2006;98(19):1375–82.PubMedCrossRef

48.

Boudova L, Kazakov DV, Sima R, et al. Cutaneous lymphoid hyperplasia and other lymphoid infiltrates of the breast nipple: a retrospective clinicopathologic study of fifty-six patients. Am J Dermatopathol. 2005;27(5):375–86.PubMedCrossRef

49.

Colli C, Leinweber B, Müllegger R, Chott A, Kerl H, Cerroni L. Borrelia burgdorferi-associated lymphocytoma cutis: clinicopathologic, immunophenotypic, and molecular study of 106 cases. J Cutan Pathol. 2004;31(3):232–40.PubMedCrossRef

50.

De la Fouchardiere A, Vandenesch F, Berger F. Borrelia-associated primary cutaneous MALT lymphoma in a nonendemic region. Am J Surg Pathol. 2003;27(5):702–3.PubMedCrossRef

51.

Cerroni L, Zoohling N, Piitz B, Kerl H. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol. 1997;24(8):457–61.PubMedCrossRef

52.

Goodlad JR, Davidson MM, Hollowood K, et al. Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the highlands of Scotland. Am J Surg Pathol. 2000;24(9):1279–85.PubMedCrossRef

53.

Bertolotti A, Pham-Ledard A, Petrot D, et al. Two cases of proliferation of monoclonal and monotypic lymphocytes and plasma cells corresponding to acrodermatitis chronica atrophicans. Ann Dermatol Venereol. 2014;141(6–7):452–7.PubMedCrossRef

54.

Fühler M, Ottmann KW, Tronnier M. Cutaneous marginal zone lymphoma (SALT) and infection with Borrelia burgdorferi. Hautarzt. 2010;61(2):145–7.PubMedCrossRef

55.

Roggero E, Zucca E, Mainetti C, et al. Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. Hum Pathol. 2000;31(2):263–8.PubMedCrossRef

56.

Ponzoni M, Ferreri AJM, Mappa S, et al. Prevalence of Borrelia burgdorferi infection in a series of 98 primary cutaneous lymphomas. Oncologist. 2011;16(11):1582–8.PubMedCentralPubMedCrossRef

57.

Kodama K, Massone C, Chott A, Metze D, Kerl H, Cerroni L. Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients. Blood. 2005;106(7):2491–7.PubMedCrossRef

58.

Goteri G, Ranaldi R, Simonetti O, et al. Clinicopathological features of primary cutaneous B-cell lymphomas from an academic regional hospital in central Italy: no evidence of Borrelia burgdorferi association. Leuk Lymphoma. 2007;48(11):2184–8.PubMedCrossRef

59.

Kempf W, Kazakov DV, Buechner SA, et al. Primary cutaneous marginal zone lymphoma in children: a report of 3 cases and review of the literature. Am J Dermatopathol. 2014;36(8):661–6.PubMedCrossRef

60.

Monari P, Farisoglio C, Calzavara Pinton PG. Borrelia burgdorferi-associated primary cutaneous marginal-zone B-cell lymphoma: a case report. Dermatology. 2007;215(3):229–32.PubMedCrossRef

61.

Takino H, Li C, Hu S, et al. Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathological study of cases from Asia, Germany, and the United States. Mod Pathol. 2008;21(12):1517–26.PubMedCrossRef

62.

Li C, Inagaki H, Kuo T-T, Hu S, Okabe M, Eimoto T. Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathologic study of 24 Asian cases. Am J Surg Pathol. 2003;27(8):1061–9.PubMedCrossRef

63.

Wood GS, Kamath NV, Guitart J, et al. Absence of Borrelia burgdorferi DNA in cutaneous B-cell lymphomas from the United States. J Cutan Pathol. 2001;28(10):502–7.PubMedCrossRef

64.

Ben-Ayed F, Halphen M, Najjar T, et al. Treatment of alpha chain disease. Results of a prospective study in 21 Tunisian patients by the Tunisian-French Intestinal Lymphoma Study Group. Cancer. 1989;63(7):1251–6.PubMedCrossRef

65.

Akbulut H, Soykan I, Yakaryilmaz F, et al. Five-year results of the treatment of 23 patients with immunoproliferative small intestinal disease: a Turkish experience. Cancer. 1997;80(1):8–14.PubMedCrossRef

66.

Pervez S, Mumtaz K, Ullah SS, Akhtar N, Ali N, Aaqil H. Immunoproliferative small intestinal disease (IPSID). J Coll Physicians Surg Pak. 2011;21(1):57–8.PubMed

67.

Lecuit M, Suarez F, Lortholary O. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. Médecine Sci. 2004;20(6–7):638–40.CrossRef

68.

Mesnard B, De Vroey B, Maunoury V, Lecuit M. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. Dig Liver Dis. 2012;44(9):799–800.PubMedCrossRef

69.

Coeuret S, de La Blanchardiere A, Saguet-Rysanek V, et al. Campylobacter coli cultured from the stools of a patient with immunoproliferative small intestinal disease. Clin Microbiol Infect. 2014;20(9):908–11.PubMedCrossRef

Title: The Role of Infectious Agents, Antibiotics, and Antiviral Therapy in the Treatment of Extranodal Marginal Zone Lymphoma and Other Low-Grade Lymphomas
Authors: Laahn H. Foster, MD
Craig A. Portell, MD
Publication date: 01-06-2015
Publisher: Springer US
Published in: Current Treatment Options in Oncology / Issue 6/2015
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI: https://doi.org/10.1007/s11864-015-0344-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Opinion statement

Please log in to get access to this content

Other articles of this Issue 6/2015

Rhabdomyosarcoma in Adults: New Perspectives on Therapy

Preoperative Therapy for Extremity Soft Tissue Sarcomas

Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation

Immunotherapeutic Approaches to Sarcoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer